Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.

Clinical Pharmacology and Therapeutics
Sara N SalernoPharmaceuticals for Children Act - Pediatric Trials Network Steering Committee

Abstract

Physiologically-based pharmacokinetic (PBPK) modeling can potentially predict pediatric drug-drug interactions (DDIs) when clinical DDI data are limited. In infants for whom treatment of pulmonary hypertension and prevention or treatment of invasive candidiasis are indicated, sildenafil with fluconazole may be given concurrently. To account for developmental changes in cytochrome P450 (CYP) 3A, we determined and incorporated fluconazole inhibition constants (KI ) for CYP3A4, CYP3A5, and CYP3A7 into a PBPK model developed for sildenafil and its active metabolite, N-desmethylsildenafil. Pharmacokinetic (PK) data in preterm infants receiving sildenafil with and without fluconazole were used for model development and evaluation. The simulated PK parameters were comparable to observed values. Following fluconazole co-administration, differences in the fold change for simulated steady-state area under the plasma concentration vs. time curve from 0 to 24 hours (AUCss,0-24 ) were observed between virtual adults and infants (2.11-fold vs. 2.82-fold change). When given in combination with treatment doses of fluconazole (12 mg/kg i.v. daily), reducing the sildenafil dose by ~ 60% resulted in a geometric mean ratio of 1.01 for simulated AU...Continue Reading

References

Apr 29, 1999·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·D K WalkerP A Wright
Dec 14, 1999·British Journal of Clinical Pharmacology·K E KenworthyJ B Houston
Aug 10, 2000·British Journal of Clinical Pharmacology·G J MuirheadN Buss
Apr 12, 2001·British Journal of Clinical Pharmacology·R HylandD A Smith
Mar 7, 2002·British Journal of Clinical Pharmacology·Gary J MuirheadPhilip Wastall
Mar 7, 2002·British Journal of Clinical Pharmacology·Gary J MuirheadJörg Taubel
Jul 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·J Andrew WilliamsSteven A Wrighton
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Jeffrey C StevensMatthew J Zaya
Jul 26, 2005·Pharmacogenetics and Genomics·Sarah C SimMagnus Ingelman-Sundberg
May 11, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M G SoarsR J Riley
Oct 16, 2007·Journal of Biochemical and Molecular Toxicology·Ronald N Hines
Nov 28, 2007·European Journal of Clinical Pharmacology·Gary BurgessJasper Dingemanse
Mar 1, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Hei-Young KuKwang-Hyeon Liu
Sep 9, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Z E BarterA Rostami-Hodjegan
Oct 20, 2009·The Journal of Pediatrics·Robin H SteinhornDavid L Wessel
Dec 2, 2009·Archives of Disease in Childhood. Fetal and Neonatal Edition·Maurice J AhsmanRon A Mathot
Jan 12, 2011·British Journal of Clinical Pharmacology·Jean-Luc VachieryRobert Naeije
Feb 2, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Michaela MeyerJoerg Lippert
Mar 29, 2014·Clinical Pharmacokinetics·Farzaneh SalemAmin Rostami-Hodjegan
Aug 19, 2014·The Journal of Infection·Rachel G Greenberg, Daniel K Benjamin
Sep 2, 2015·Current Pharmaceutical Design·Karina ClaassenStefan Willmann
Oct 23, 2015·Clinical Therapeutics·Krystle M Perez, Matthew Laughon
Aug 17, 2016·The American Journal of Tropical Medicine and Hygiene·Rachel M BurkeJuan S Leon
May 27, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Olusola OlafuyiRaj K S Badhan
Nov 15, 2017·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ju-Hyun KimSangkyu Lee
Jul 24, 2018·CPT: Pharmacometrics & Systems Pharmacology·Kevin M WattAndrea N Edginton
May 16, 2019·CPT: Pharmacometrics & Systems Pharmacology·Jacqueline G GerhartUNKNOWN Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee
Sep 3, 2019·British Journal of Clinical Pharmacology·Daniel GonzalezUNKNOWN Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

British Journal of Clinical Pharmacology
D GonzalezBest Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee
The Medical Journal of Australia
C G McMahon
Deutsche medizinische Wochenschrift
H Sperling, M C Michel
Journal of Perinatology : Official Journal of the California Perinatal Association
A Y W FangKai König
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
Samira Samiee-ZafarghandyJohannes N van den Anker
© 2021 Meta ULC. All rights reserved